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Abstract
Aims: Among adults with type 2 diabetes (T2D), unhealthy behaviours are associated 
with increased risk of cardiovascular disease (CVD) events. To date, little research 
has considered whether healthy changes in behaviours following T2D diagnosis re-
duce CVD risk.
Methods: A cohort of 867 adults with screen- detected T2D, participating in the 
Anglo- Danish- Dutch Study of Intensive Treatment in People with Screen- Detected 
Diabetes in Primary Care (ADDITION)- Cambridge trial, were followed for 10 years 
for incidence of CVD events. Diet, alcohol consumption, moderate/vigorous physical 
activity and smoking were assessed by questionnaire at the time of T2D screening and 
1 year later. We estimated associations between health behaviours and CVD using 
Cox regression. We assessed modification of the associations by behaviour change in 
the year following T2D diagnosis.
Results: Smoking [hazard ratio (HR): 1.73 (95% CI: 1.04, 2.87)] and high fat intake 
[HR: 1.70 (95% CI: 1.02, 2.85)] were associated with a higher hazard of CVD, while 
high plasma vitamin C [HR: 0.44 (95% CI: 0.22, 0.87)] and high fibre intake [HR: 
0.60 (95% CI: 0.36, 0.99)] were associated with a lower hazard of CVD. Reduction 
in fat intake following T2D diagnosis modified associations with CVD. In particular, 
among those with the highest fat intake, decreasing intake attenuated the association 
with CVD [HR: 0.75 (95% CI: 0.36, 1.56)].
Conclusion: Following T2D diagnosis, decreasing fat intake was associated with 
lower long- term CVD risk. This evidence may raise concerns about low- carbohydrate, 
high- fat diets to achieve weight loss following T2D diagnosis. Further research con-
sidering the sources of fat is needed to inform dietary recommendations.
Trial registration: This trial is registered as ISRCTN86769081. Retrospectively reg-
istered on 15 December 2006.
K E Y W O R D S
alcohol drinking, cardiovascular diseases, diabetes mellitus, type 2, diet, exercise, health behaviour, 
smoking
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1 |  INTRODUCTION
Health behaviours contribute to the development and pro-
gression of type 2 diabetes (T2D), including the risk of 
cardiovascular disease (CVD) complications.1- 3 Moderate 
levels of physical activity, a nutritionally balanced diet and 
smoking cessation are recommended for the management 
of T2D.4 Studies have suggested that healthy changes in 
these behaviours after T2D diagnosis may reduce CVD 
risk.5- 8 However, these studies have not explored whether 
the association between changes in diet or physical activ-
ity and CVD outcomes varies according to baseline levels 
of these behaviours.
Previously, The Anglo- Danish- Dutch Study of Intensive 
Treatment in People with Screen- Detected Diabetes in 
Primary Care (ADDITION)- Cambridge trial found that 
participants who increased their physical activity fol-
lowing T2D diagnosis had a lower 5- year risk of CVD 
events compared to participants who did not.7 Baseline 
differences in physical activity among participants who 
increased activity levels, compared to those who did not, 
may have contributed to the observed association, but this 
was not explored. To date, little research has investigated 
whether associations between physical activity levels and 
CVD are modified by changes in physical activity follow-
ing T2D diagnosis.
Dietary behaviours, such as higher fibre intake, have 
been associated with lower risk factors for CVD in peo-
ple with T2D.9 Additionally, changes in these behaviours 
following T2D diagnosis, such as increasing fruit and veg-
etable intake, have been associated with reduced CVD risk 
factors.5 Separately, ADDITION- Cambridge previously 
found that reducing alcohol consumption in the year fol-
lowing T2D diagnosis lowered 5- year and 10- year inci-
dence of CVD events.7,8 However, whether the effect of 
dietary behaviours and alcohol consumption on CVD risk 
is modified by behaviour changes following T2D diagnosis 
remains to be established.
T2D diagnosis may be a ‘teachable moment’ when those 
diagnosed become aware of the benefits of adopting healthier 
behaviours. Participants in the ADDITION- Cambridge co-
hort were newly diagnosed with screen- detected T2D at time 
of enrolment and were therefore at an early stage of disease 
progression. Behaviour changes may affect people differently 
depending on their behaviours at the time of T2D diagnosis. 
We aimed to identify whether changes in behaviours impacted 
the association between behaviours prior to T2D diagnosis 
and long- term CVD risk. Our objectives were to evaluate the 
associations between health behaviours at diagnosis and the 
10- year incidence of CVD, and to assess whether behaviour 
changes made within the first year following diagnosis mod-
ified these associations.
2 |  METHODS
2.1 | Population
ADDITION- Cambridge is a population- based screening 
programme for T2D, followed by a cluster- randomized in-
tervention trial to evaluate the effectiveness of intensive 
multifactorial treatment compared to routine care in reducing 
CVD risk in those with screen- detected T2D.10,11 Screening 
invitations were sent to 33,539 individuals who met eligibil-
ity criteria: aged 40– 69 years, at high risk of undiagnosed di-
abetes and registered at a participating general practice (GP) 
within Eastern England (n = 49).10 High risk was determined 
by a validated risk tool using routinely collected informa-
tion from participants’ medical records.12 Of those invited, 
73.5% attended the first stage of screening.13 Diabetes was 
diagnosed according to World Health Organization criteria 
(1999).14 This identified a cohort of 867 individuals with 
screen- detected T2D, all of whom consented to participate 
in the treatment study and were enrolled between 2002 and 
2006. Participants at practices randomized to routine care 
(n = 23) received diabetes care according to National Health 
Service guidelines.10 Participants at practices randomized to 
intensive treatment (n = 26) received more frequent consulta-
tions and educational material packs on healthy behaviours, 
while physicians were encouraged to follow a protocol that 
featured earlier use of medication to achieve more intensive 
treatment targets.10 Results suggested that the intervention 
did not significantly improve CVD outcomes.11 Thus, data 
Novelty statement:
What is already known on this subject?
• Diet and physical activity are risk factors for 
type 2 diabetes (T2D) and cardiovascular disease 
(CVD).
• Little research has assessed whether changes in 
these behaviours following T2D diagnosis modify 
CVD risk.
What has this study found?
• High fat intake was associated with higher 10- year 
hazard of CVD. However, reducing fat intake in 
the year after T2D diagnosis attenuated this risk.
What are the clinical implications of the study?
• Among those with newly diagnosed T2D, reduc-
ing fat intake may lower long- term risk of CVD. 
This suggests caution is warranted regarding the 
increasing use of low carbohydrate diets to treat 
CVD, as such diets typically result in increases in 
fat intake.
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from the two arms were pooled for the present study: an ob-
servational secondary analysis of the ADDITION- Cambridge 
cohort. Ethical approval was obtained from relevant Multi- 
Centre Research Ethics Committees.10
2.2 | Measurements
Smoking, alcohol consumption, physical activity, fibre, 
total energy and fat intake, were ascertained by self- report, 
while plasma vitamin C was measured using a fluorometric 
assay.10 All behaviours were measured at baseline (T2D di-
agnosis) and 1 year later. Physical activity was assessed by 
the validated European Prospective Investigation into Cancer 
(EPIC)- Norfolk Physical Activity Questionnaire10 and was 
defined as moderate/vigorous physical activity (MVPA) in 
the past year. Fibre, total energy and fat intakes over the past 
year were estimated by the validated EPIC- Norfolk food 
frequency questionnaire.10 Smoking status (never, former, 
current), alcohol consumption (units/week), MVPA (min-
utes/week), plasma vitamin C (μmol/l), fibre intake (g/day), 
total energy intake (Kcal/day) and percentage of total energy 
intake from fat (%) are targets of healthy behaviour recom-
mendations for those with T2D. Body mass index (BMI) was 
derived from measures at baseline using a fixed rigid stadi-
ometer and SECA scales. Socio- demographic information 
(age, sex, age left full- time education, occupational social 
class) and prescribed medication use were also self- reported 
at baseline.
2.3 | CVD outcomes
CVD outcomes were assessed from date of T2D diagnosis 
to 31 December 2014 and were defined as a composite of 
first cardiovascular event during the study period, including 
cardiovascular mortality, non- fatal myocardial infarction, 
non- fatal stroke, non- traumatic amputation and revasculari-
zation.10 National registers, hospital and GP records were 
used to ascertain incidence of non- fatal CVD events, while 
Office of National Statistics mortality data was used to as-
certain incidence of deaths.7,10 All events were indepen-
dently adjudicated. Outcomes were ascertained for 99.9% of 
participants.13
2.4 | Statistical analysis
2.4.1 | Health behaviours and CVD incidence
Continuous values of plasma vitamin C, fibre intake, 
total energy intake, percentage of total energy from fat 
and MVPA were categorized in quartiles. Supplemental 
analyses considered percentage of energy from saturated fat 
and mono- and poly- unsaturated fats. For alcohol consump-
tion, categories of abstainer (0 units/week), light– moderate 
(1– 14 units/week) and heavy (>14 units/week) were used. 
Referent groups were quartile one for all health behaviours 
except total energy intake (which used quartile three), smok-
ing (never) and alcohol consumption (1– 14 units/week). 
Hazard ratios (HRs) for the association between each health 
behaviour at baseline and 10- year CVD incidence were esti-
mated by Cox proportional hazards regression. Participants 
were at risk for an incident CVD event from date of T2D 
diagnosis. Follow- up time was censored at the earlier of first 
CVD event, non- CVD death, or 31 December 2014. The 
Schoenfeld residuals test and log- log survival curves indi-
cated no violations of the proportional hazards assumption.
All models were adjusted for age (continuous), sex (men/
women), occupational social class (managerial/professional, 
intermediate, routine/manual), age left full- time education 
(<16 years, 16– 18 years, >18 years), baseline BMI (contin-
uous), baseline anti- hypertensive medication use (yes/no), 
baseline lipid- lowering medication use (yes/no), treatment 
group (intervention/routine care) and baseline smoking sta-
tus where smoking was not the primary exposure (current, 
never/former). Confounders were selected a priori and were 
variables previously established to be associated with the ex-
posure and outcome. We did not adjust for glucose- lowering 
medication use because only four participants reported use 
at baseline. Robust standard errors accounted for clustering 
by GP.
We performed a complete case analysis. Individuals were 
excluded from an analysis if they were missing behaviour or 
covariate information. Separately, we performed a sensitivity 
analysis excluding 99 participants who reported having a his-
tory of CVD prior to enrolment.
2.4.2 | Behaviour change and CVD incidence
To assess whether behaviour changes made in the year fol-
lowing T2D diagnosis modified the baseline associations, 
we modelled an interaction term between the behaviour at 
baseline and behaviour change between baseline and 1 year. 
Behaviour change was defined as the value at baseline sub-
tracted from the value at 1  year. In these models, the risk 
period for CVD events began at the 1- year follow- up visit. 
Modification by change in smoking status was not investi-
gated as too few participants changed their smoking status 
(n = 21). The testparm command was used to assess the pres-
ence of statistically significant interaction simultaneously 
across the categories of each health behaviour. A Wald test 
p- value <0.05 suggested that change in behaviour modified 
the baseline association with CVD. We then assessed if the 
presence of modification differed depending on baseline 
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exposure category. HRs for the association between a one 
standard deviation (SD) increase and decrease in each health 
behaviour with CVD were calculated from the linear combi-
nation of estimates generated from the models. These HRs 
were then compared to the HRs unadjusted for interaction 
terms to examine whether behaviour change modified the 
baseline association between the behaviour and CVD risk.
3 |  RESULTS
Of the 867 study participants, median age at diagnosis was 
62.7  years and 61% were men (Table  1). Mean baseline 
BMI was 33 kg/m2. There were 126 CVD events during the 
study period: 31 CVD deaths, 21  myocardial infarctions, 
33 strokes, 40 revascularizations and one amputation. Mean 
follow- up time was 9.6  years from T2D diagnosis. Seven 
hundred and fifty- eight (87%) participants attended for 1- 
year measurements.
Compared to never smokers, former and current smok-
ers had a higher hazard of CVD, with HRs of 1.61 (95% 
CI: 1.07, 2.42) and 1.73 (95% CI: 1.04, 2.87) respectively 
(Table 2). Those in the highest quartile of fat intake had a 
higher hazard of CVD compared to participants with the 
lowest intake [HR: 1.70 (95% CI: 1.02, 2.85)]. Compared to 
those with the lowest levels of plasma vitamin C, those with 
the highest levels had a 56% lower hazard of CVD (95% CI: 
0.22, 0.87). Those with the highest fibre intake had a lower 
hazard of CVD compared to those with the lowest intake 
[HR: 0.60 (95% CI: 0.36, 0.99)]. Results were robust to the 
inclusion of participants with a CVD history prior to diag-
nosis (Table S1).
The association between percentage of energy from fat 
and CVD was modified by changes in fat intake in the year 
following T2D diagnosis (p- value for interaction term: 0.04). 
Among those in the highest quartile of fat intake at baseline, 
a one SD (6.48%) increase in energy from fat was associ-
ated with a higher hazard of CVD [HR: 4.20 (95% CI: 1.48, 
11.89)], while a 6.48% decrease was not associated with CVD 
[HR: 0.75 (95% CI: 0.36, 1.56)] (Table 3). A 6.48% decrease 
among those in the second and third quartiles of fat intake, 
although not statistically significant, showed a lower haz-
ard of CVD, [HR: 0.76 (95% CI: 0.30, 1.94)] and [HR: 0.50 
(95% CI: 0.21, 1.17)] respectively. Analyses separating per-
centage of energy from saturated and unsaturated fat showed 
no statistically significant associations with CVD (Table 
S2). Modification of these associations by 1- year changes in 
saturated or unsaturated fat intake was not statistically sig-
nificant. However, increases in saturated fat intake among in-
dividuals with high baseline saturated fat intake appeared to 
correspond with an increase 10- year hazard of CVD. Among 
individuals who reduced their saturated fat intake, there was 
no elevated risk of CVD (Table S3).
The Wald test p- value for overall interaction was >0.05 
for other behaviours (Table 3). However, the magnitudes of 
the stratified HRs for plasma vitamin C and MVPA, while 
not statistically significant, suggest the potential for modi-
fication by behaviour change. For plasma vitamin C, a one 
SD (22.85 μmol/L) decrease showed a higher hazard of CVD 
among those in the third highest quartile of intake [HR: 1.70 
(95% CI: 0.68, 4.29)]. For MVPA, a one SD (860.31 min/
week) decrease was associated with a higher hazard of CVD 
among those in the second, third and fourth quartiles [HR: 
3.86 (95% CI: 0.68, 21.72)], [HR: 3.18 (95% CI: 1.16, 8.78)] 
and [HR: 1.59 (95% CI: 0.73, 3.43)] respectively. For alcohol 
consumption, fibre intake and total energy intake, the results 
provided no indication of modification by behaviour change.
4 |  DISCUSSION
Among the 867 adults with screen- detected T2D enrolled in 
ADDITION- Cambridge, current or former smoking and a 
high percentage of energy from fat were associated with a 
higher hazard of 10- year CVD incidence, while higher levels 
of plasma vitamin C and fibre intake were associated with 
a lower hazard of CVD incidence. The association between 
percentage of energy from fat and CVD risk was modified 
by changes in fat intake in the year following T2D diagno-
sis, where a 6.48% decrease attenuated the association with 
CVD. We did not detect statistically significant modification 
of the associations between other behaviours and CVD.
To date, little research has assessed the impact of within- 
individual changes in health behaviours following T2D diag-
nosis on CVD events. We found that, while high fat intake 
was associated with elevated CVD risk, there was no elevated 
risk of CVD among those who had decreased their fat intake 
in the year after T2D diagnosis. Saturated fat showed simi-
lar but non- statistically significant associations with CVD, 
while unsaturated fat intake was not associated with CVD 
risk. This may suggest that the observed association between 
fat intake and CVD may be primarily driven by changes in 
saturated fat as opposed to unsaturated fat intake. However, 
future research focused on dietary sources of fat intake would 
be better suited to address this question. This result is sup-
ported by a recent meta- analysis which showed that reduc-
tions in saturated fat lowered risk of CVD events15 and one 
study has reported this among individuals with T2D.16 These 
findings are particularly relevant given the recent popular-
ity of low- carbohydrate diets for T2D treatment. The effects 
of low- carbohydrate diets on CVD risk remain unclear,17,18 
however several studies have found that low- carbohydrate 
diets, particularly those coupled with high animal fat in-
take, are associated with higher all- cause mortality rates.19- 21 
Our research supports that a diet leading to higher fat intake 
may increase long- term CVD risk, which raises concerns 
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regarding low- carbohydrate high- fat approaches. However, 
further research considering the sources of fat is needed to 
inform dietary recommendations.
Prior research has shown that increased MVPA follow-
ing T2D diagnosis lowers CVD risk.7 We did not identify 
any impacts of increases in physical activity on the observed 
associations with CVD, perhaps due to the small average in-
creases in activity (27.76 min/week), and the low power of the 
effect modification analyses. For this reason, the lack of evi-
dence from this study on the effect of increases in MVPA on 
CVD should not undermine the established benefits of phys-
ical activity on CVD risk. Furthermore, we did not detect an 
T A B L E  1  Characteristics of study participants at baseline by cardiovascular disease (CVD) status at 10- year follow- up. Data are presented as n 
(%) unless stated otherwise. ADDITION- Cambridge 2002– 2014 (n = 867)
Variable Category/Unit n (%) CVD event (n = 126)
No CVD event 
(n = 741)
Socio- demographic
Ageb Years 867 (100) 65 (59, 69) 62 (56, 67)
867 (100)
Sex Men 530 (61) 94 (18) 436 (82)
Women 337 (39) 32 (9.5) 305 (91)
Occupational social class 847 (98)
Managerial/ Professional 278 (33) 38 (14) 240 (86)
Intermediate 197 (23) 24 (12) 173 (88)
Routine/ Manual 372 (44) 59 (16) 313 (84)
Age left full- time education 851 (98)
<16 years 418 (49) 64 (15) 354 (85)
16– 18 years 335 (39) 45 (13) 290 (87)
>18 years 98 (12) 14 (14) 84 (86)
Clinical
Body mass indexa kg/m2 862 (100) 33.1 (6.4) 33.5 (5.6)
Glucose- lowering medication 865 (100)
Yes 4 (0.5) 1 (25) 3 (75)
Anti- hypertensive medication 865 (100)
Yes 499 (58) 85 (17) 414 (83)
Lipid- lowering medication 865 (100)
Yes 209 (24) 52 (25) 157 (75)
Treatment group 867 (100)
Intervention 452 (52) 62 (14) 390 (86)
Routine care 415 (48) 64 (15) 351 (85)
Health behaviours measured at baseline
Smoking status 866 (100)
Current 157 (18) 25 (16) 132 (84)
Alcohol consumptionb units/week 853 (98) 3 (0, 9) 3 (0, 10)
MVPAb minutes/week 864 (100) 577.9 (197.5, 1072.3) 541.4 (213.4, 
1195.6)
Plasma vitamin Ca μmol/l 779 (90) 48.4 (23.6) 53.0 (22.5)
Fibre intakea g/day 855 (99) 15.9 (7.5) 17.0 (6.7)
Total energy: Mena Kcal/day 523 (99) 2110.5 (717.8) 2038.5 (735.9)
Total energy: Womena Kcal/day 330 (98) 1825.4 (1057.4) 1842.5 (607.2)
Percentage of energy from fata % 855 (99) 33.8 (6.7) 32.8 (6.1)
Abbreviation: MVPA, Moderate/Vigorous Physical Activity.
aData are presented as mean (SD) for normally distributed variables.
bData are presented as median (25th, 75th percentile) for non- normally distributed variables.
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association between changes in plasma vitamin C and CVD, 
although this has been demonstrated previously.5,16 The null 
association in our study may also be due to the small average 
changes in plasma vitamin C levels (1.99 μmol/L) as well as 
the low power of the stratified effect modification analyses.
A recent ADDITION- Cambridge analysis found reduc-
ing alcohol consumption by >2 units/week was associated 
with lower 10- year hazard of CVD.8 However, our results did 
not find changes in alcohol consumption following T2D di-
agnosis to modify the association between baseline alcohol 
consumption and CVD. One key distinction is that in this 
analysis we did not count abstainers among those who re-
duced their alcohol intake. The average change among mod-
erate drinkers was insubstantial, which may have limited our 
ability to detect modification, further impacted by the low 
power of the stratified analyses. Additionally, changes in 
fibre intake and total energy intake were not found to modify 
the baseline associations with CVD. This may be because the 
average changes in fibre intake and total energy intake, aside 
from the group with the highest total energy intake at base-
line, were small.
A key limitation of this study is the low number of events, 
which may have impacted our ability to detect associations. 
Stratified models assessing modification by behaviour change 
compromise statistical power, limiting our ability to detect 
effect modification. Results for alcohol consumption, fibre 
intake and total energy intake suggest an absence of interac-
tion on the multiplicative scale, however, we did not assess 
interaction on the additive scale. Additionally, results are sen-
sitive to how behaviour change has been defined. A one SD 
change may constitute quite a large behaviour change (e.g. 
increasing fibre intake by 11  g/day equates to eating three 
pears), and the average behaviour changes among the cohort 
were generally small. Behaviour change was measured 1 year 
after diagnosis and may not have been maintained long term. 
It is possible that changes in behaviours may take longer than 
10  years to generate differences in CVD risk. Despite the 
small number of events and small changes in behaviours, it is 
evident that increases in fat intake may be harmful. We can-
not exclude the possibility that changes in other behaviours 
may be beneficial or harmful in circumstances where larger 
changes are achieved and where changes are maintained for 
longer periods of time.
Another limitation is the exposure assessment. Except 
for plasma vitamin C, behaviours were ascertained by self- 
report, which may result in exposure misclassification and 
would consequently attenuate the observed associations. 
Social desirability bias may have influenced reporting of 
health behaviours,22 including alcohol consumption and 
smoking. Additionally, weight- dependent bias may have re-
sulted in those with higher BMI under- reporting dietary in-
takes. Furthermore, we tested for effect modification by six 
variables, and while we did not correct for multiple testing, 
T A B L E  2  Hazard ratios for 10- year cardiovascular disease 
(CVD) incidence associated with each health behaviour at baseline. 





Hazard ratio (95% 
CI) for CVDa 
Smoking status
Never 27/291 1
Former 69/388 1.61 (1.07, 2.42)
Current 23/148 1.73 (1.04, 2.87)
Alcohol (units/week)
1– 14 66/425 1
0 34/241 1.04 (0.60, 1.78)
>14 18/150 0.77 (0.46, 1.28)
MVPA (minutes/week)
Q1 (0– 210.5) 30/199 1
Q2 (545.0) 23/212 0.80 (0.47, 1.39)
Q3 (1178.9) 39/209 1.32 (0.77, 2.27)
Q4 (6902.7) 27/205 0.80 (0.49, 1.33)
Plasma vitamin C (μmol/L)
Q1 (2.9– 36.7) 35/189 1
Q2 (53.6) 23/187 0.67 (0.42, 1.09)
Q3 (67.2) 31/184 0.93 (0.55, 1.59)
Q4 (129.3) 16/185 0.44 (0.22, 0.87)
Fibre intake (g/day)
Q1 (3.0– 12.1) 43/204 1
Q2 (15.7) 24/206 0.54 (0.34, 0.86)
Q3 (19.3) 25/207 0.56 (0.30, 1.02)
Q4 (48.0) 25/200 0.60 (0.36, 0.99)
Total energy (Kcal/day)b 
Q1 (M: 558.6– 1580.8)
(W: 519.4– 1420.8)
32/202 1.16 (0.69, 1.96)
Q2 (M: 1932.6)
(W: 1744.7)
26/205 1.03 (0.60, 1.77)





31/203 1.45 (0.89, 2.34)
Percentage of energy from 
fat (%)
Q1 (12.6– 29.1) 26/202 1
Q2 (33.1) 32/210 1.35 (0.77, 2.36)
Q3 (37.2) 22/206 0.95 (0.53, 1.70)
Q4 (56.3) 37/199 1.70 (1.02, 2.85)
Abbreviations: MVPA, Moderate/Vigorous Physical Activity, Q1/2/3/4, 
Quartile 1/2/3/4.
aAdjusted for age, sex, age left full- time education, occupational social class, 
baseline body mass index, baseline anti- hypertensive medication use, baseline 
lipid- lowering medication use, treatment group and baseline smoking status 
where smoking was not the primary exposure variable. All models accounted for 
clustering by general practice.
bQuartile cut points given for men (‘M’) and women (‘W’) separately.
cReferent group for total energy intake is Q3.
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T A B L E  3  Hazard ratios for 10- year cardiovascular disease (CVD) incidence associated with a one standard deviation (SD) increase and 





cases / n 
total
Wald test 
p- value** Mean (SD) behaviour change
Hazard ratio (95% CI) 
for a 1 SD increasea 
Hazard ratio (95% CI) for a 




1– 14 59/379 −0.02 (4.65) 1 1
0 20/186 0.23 (0.73) 0.71 (0.01, 46.44) n/a





Q1 (0– 210.5) 19/163 204.26 (432.85) 1 1
Q2 (545.0) 17/181 245.63 (456.58) 0.42 (0.14, 1.28) 3.86 (0.68, 21.72)
Q3 (1178.9) 34/187 166.57 (710.32) 1.18 (0.54, 2.62) 3.18 (1.16, 8.78)




Q1 (2.9– 36.7) 24/155 13.97 (18.40) 1 1
Q2 (53.6) 18/150 4.96 (20.90) 0.78 (0.39, 1.58) 0.60 (0.21, 1.71)
Q3 (67.2) 27/155 −0.29 (21.04) 0.68 (0.30, 1.55) 1.70 (0.68, 4.29)




Q1 (3.0– 12.1) 31/161 3.56 (5.29) 1 1
Q2 (15.7) 19/173 2.76 (5.41) 0.57 (0.14, 2.27) 0.50 (0.07, 3.42)
Q3 (19.3) 22/189 3.45 (17.26) 0.67 (0.28, 1.59) 0.57 (0.17, 1.97)




























23/178 2.69 (6.36) 1 1
(Continues)
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we interpreted results with caution considering the magni-
tude and precision of the estimates, in light of the large num-
ber of tests run. Participants were invited to the screening 
programme based on a diabetes risk score which selected in-
dividuals with higher BMI. It is possible that the cohort may 
be more (or less) responsive to changes in diet than individu-
als with lower BMI. Finally, the majority of participants had 
overweight/obesity at the time of T2D diagnosis and were 
white. Thus, results from this study may not be generalizable 
to other groups. It is possible that the observed associations 
between dietary fat and CVD risk may vary among sub- 
groups with different diabetes characteristics or cardiovascu-
lar risk factors, and future research with the appropriate data 
should explore this question.
ADDITION- Cambridge had a high attendance at screen-
ing and all eligible individuals identified with T2D consented 
to enrol. Since T2D was screen detected and behaviour mea-
surements were repeated the year after diagnosis, this study 
was able to assess behaviour change early in T2D progres-
sion. This ability, along with the population- based nature of 
the study, are particular strengths compared to other research 
on health behaviours among adults with T2D. Other strengths 
are the objective assessment of plasma vitamin C, a marker of 
fruit and vegetable intake, and the independent adjudication 
of CVD events.
This study emphasizes the importance of healthy vitamin 
C, fibre and fat intake, and the prevention of smoking in re-
ducing CVD risk among those with T2D. Additionally, these 
results support recommending those newly diagnosed with 
T2D to reduce their fat intake, as this may lower their haz-
ard of CVD incidence and mitigate effects of a high- fat diet 
on long- term CVD risk. This evidence may raise concern re-
garding low- carbohydrate diets in diabetes treatment, as these 
diets typically lead to increases in fat intake. Future research 
incorporating data on the sources of fat intake are needed to 
inform dietary recommendations. Few studies have assessed 
long- term health impacts of changes in behaviours follow-
ing T2D diagnosis and further research is needed to support 
these results. Future studies using objective behaviour mea-
surements and with longer follow- up will help to better our 
understanding of the role of behaviour changes following 
T2D diagnosis in the prevention of CVD.
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cases / n 
total
Wald test 
p- value** Mean (SD) behaviour change
Hazard ratio (95% CI) 
for a 1 SD increasea 
Hazard ratio (95% CI) for a 
1 SD decreasea 
Q2 (33.1) 27/181 −1.66 (5.40) 1.67 (0.59, 4.72) 0.76 (0.30, 1.94)
Q3 (37.2) 16/176 −3.49 (5.23) 0.97 (0.33, 2.86) 0.50 (0.21, 1.17)
Q4 (56.3) 27/165 −5.24 (6.22) 4.20 (1.48, 11.89) 0.75 (0.36, 1.56)
Abbreviations: MVPA, Moderate/Vigorous Physical Activity, Q1/2/3/4, Quartile 1/2/3/4.
aHazard ratios calculated from the linear combination of estimates generated from proportional hazards regression models for the association between each health 
behaviour and CVD.
bQuartile cut points given for men (‘M’) and women (‘W’) separately.
cReferent group for total energy intake is Q3.
*10 participants were excluded since they experienced a CVD event or non- CVD death in the first year of follow- up.; **p- value for the test of no interaction between 
the health behaviour at baseline and behaviour change, across all categories of the health behaviour.
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